Release date: 2015-10-22
With a newly discovered rare human antibody, scientists at the Scripps Research Institute in the United States converted leukemia cells into immune cells that fight leukemia, killing them "self-killing." The results, published this week in the Proceedings of the National Academy of Sciences, are expected to bring powerful new therapies against leukemia and even other cancers.
The official website of the Scripps Research Institute released a press release on the 19th (US time) that the laboratory of Richard Lerner, a senior researcher and professor of immunochemistry, pioneered a technology that can generate large antibodies (immune system molecules). The library selects therapeutic antibodies that bind to the target or activate the target receptor on the cell. The researchers found that some receptor-activated antibodies have unexpected effects on bone marrow cells that can cause them to develop into completely different types of cells, such as nerve cells. Then, after 20 recently tested receptor activation antibodies against acute myeloid leukemia cells, the researchers found an antibody that allows healthy immature bone marrow cells to develop into platelet-producing megakaryocytes. Let acute myeloid leukemia cells mature into completely different cells - dendritic cells that are antigenic in the immune system. When exposed to the antibody for a prolonged period of time, coupled with specific culture conditions, these induced dendritic cells can be further differentiated into cells that are highly similar to natural killer (NK) cells - inducing NK cells.
Under electron microscopy, there are many induced NK cells that have already placed tendrils into the outer membrane of adjacent leukemia cells. Petri dish tests showed that a moderate number of induced NK cells had eliminated 15% of acute myeloid leukemia cells in just 24 hours. Surprisingly, the cancer-inducing effect of inducing NK cells seems to be purely "hand and foot disability", and unrelated breast cancer cells do not die in large numbers.
This "killing" therapy has some potential advantages. First, as antibodies, they can be applied to the clinic with little further modification. Second, the therapy has high specificity, and the possibility of adverse side effects should be lower, which is more tolerable than traditional chemotherapy. Third, the method It is expected that each cancer cell will be transformed into a cancer-killing NK cell, and eventually the cancer cell will be completely eliminated.
Lerner said that this is a new anti-cancer strategy, they are talking with pharmaceutical companies, after the pre-clinical toxicity study, human body test directly.
Editor-in-chief
Cancer cells are like a group of good people who have fallen into the bandits of the siege. The new treatment plan is like rebelling against the rebels and letting them get angry. The development of key dendritic cells in the immune system is still a mystery. Scientists try to rate it as they explore its temper. Perhaps dendritic cells can do more for us.
Source: China Science and Technology Network - Technology Daily
Diagnostic reagents can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents. It is mostly a reagent for detection by the reaction between antigen and antibody.
A: Classification of in vitro diagnostic reagents:
1. In vitro biodiagnostic reagents managed as drugs include:
1. Blood type and tissue type reagents;
2. Microbial antigen, antibody and nucleic acid detection reagents;
3. Tumor marker reagents;
4. Immunohistochemistry and human tissue cell reagents;
5. Human genetic testing reagents;
6. Biochips;
7. Allergy diagnostic reagents.
2. In vitro reagents managed as medical devices include:
1. Clinical basic test reagents;
2. Clinical chemistry reagents;
3. Blood gas and electrolyte determination reagents;
4. Vitamin determination reagents;
5. Cell histochemical stains;
6. Autoimmune diagnostic reagents;
7. Microbiological test reagents.
B: According to medical test items, clinical diagnostic reagents can be roughly divided into clinical chemical test reagents, immunology and
Serological testing reagents, hematological and cytogenetic testing reagents, microbiological testing reagents, body fluid excretion
Detection reagents, genetic diagnosis reagents, etc. Among them, the market share of clinical chemistry
The largest, close to 34%; followed by the immunology market, accounting for about 29%. Novel immunodiagnostic reagents and genetic diagnostic tests
The reagent was developed in the late 1980s, and it is the most common diagnostic reagent for all current diagnostic reagents, regardless of technology or market.
The fastest growing product.
Urine Rapid Test Kit,Rapid Test Kit 6-Panel,Toxoplasma rapid test kits,Fecal Occult Blood Test
Jilin Sinoscience Technology Co. LTD , https://www.jilinsinoscience.com